Kallikrein-related peptidases (KLKs) and the hallmarks of cancer

Panagiota S. Filippou, George S. Karagiannis, Natasha Musrap, Eleftherios P. Diamandis

    Research output: Contribution to journalReview articlepeer-review

    11 Citations (Scopus)


    Abstract: The kallikrein-related peptidases (KLKs) represent the largest family of serine proteases within the human genome and are expressed in various tissues. Although they regulate several important physiological functions, KLKs have also been implicated in numerous pathophysiological processes, including cancer. Growing evidence describing the deregulation of KLK expression and secretion, as well as activation in various malignancies, has uncovered their potential as mediators of cancer progression, biomarkers of disease and as candidate therapeutic targets. The diversity of signalling pathways and proteolytic cascades involving KLKs and their downstream targets appears to affect cancer biology through multiple mechanisms, including those related to the hallmarks of cancer. The aim of this review is to provide an update on the importance of KLK-driven molecular pathways in relation to cancer cell traits associated with the hallmarks of cancer and to highlight their potential in personalized therapeutics.

    Original languageEnglish
    Pages (from-to)277-291
    Number of pages15
    JournalCritical Reviews in Clinical Laboratory Sciences
    Issue number4
    Publication statusPublished - 3 Jul 2016


    Dive into the research topics of 'Kallikrein-related peptidases (KLKs) and the hallmarks of cancer'. Together they form a unique fingerprint.

    Cite this